1200 AVENUE OF THE AMERICAS, NEW YORK, X1
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Investor Presentation
Director Resignation - Tamar Howson Steps Down from Board
Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Q2
Q1
Amended Annual Report
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership